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Introduction: Glioblastoma Multiforme (GBM), a type of primary brain tumor is 
found to account for almost 80% of these tumors and, therefore, signifying the frequent 
occurrence. In Malaysia, a constantly increasing incidence along with limitations on 
currently available therapy options had urged the need for newer approaches to be 
implemented. For centuries, honey, a sweet natural product has been described in 
traditional medicine for its various medicinal uses. However, until recently honeys have 
been both researched scientifically and exploited medicinally on its various kinds of 
photochemical constituents. 
Objectives: The study is aimed to evaluate the anticancer activity of honey sample 
produced by a stingless bee species (Heterotrigona itama sp) for morphological analysis 
and cytotoxic activity against malignant brain tumor cells to provide evidence on its 
anticancer effect. 
Methods: Human primary glioblastoma cell line; U87 and dBTRG, are grown 
exponentially and treated with honey concentrations of 2-10% for three sequential days 
(24h, 48h, 72h). Honey sample from the stingless bee Heterotrigona Itama sp. were 
collected under sterile condition. The cytotoxicity of honey is quantified using colorimetric 
MTS assay with treatment of 2-10% of stingless bee honey. The plates were incubated and 
absorbance value was measured using ELISA reader at 490nm. For morphological analysis, 
the cell lines were seeded into six-well plates, and treated with 2% to 10% concentration of 
the honey for 24, 48 and 72 hours. At the indicated time points, morphological changes 
were examined and recorded under light microscope. Apoptosis was determined at similar 
intervals and concentrations after staining the cells with a nucleic acid stain known as 
Acridine Orane/Propidum Iodide. 
Results: Overall, crude honey sample have higher cytotoxic activities on U87 than 
dBTRG cell lines in a dose dependent manner, with U87 cell line showing higher 
sensitivity towards the honey extract. For morphological analysis, honey treated cells 
exhibited morphological alteration such as nuclear shrinkage, chromatin condensation and 
fragmented nucleus indicating apoptotic cellular changes. 
Conclusion: In conclusion, Heterotrigona Itama sp. contains an in vitro cytotoxic 
activity against human glioma cell lines, therefore suggesting the anticancer effect of the 
stingless bee honey. Further study is however required which includes isolation and 
characterization of the anticancer agents. 
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CHAPTER 1 
 
 
INTRODUCTION 
 
 
1.1  Study background 
Two percent of human malignancies are by primary tumor of central nervous 
system (CNS). Malignant gliomas/glioblastoma (GBM) known as one of the 
most aggressive neoplasm, had been the most commonly occurring CNS tumors. 
The annual incidence of malignant gliomas is approximately 5 cases per 100,000 
people (WHO, 2008). It’s incidence in Malaysia had shown to constantly 
increase through the years with GBM contributing the most (Yusoff et al., 2004). 
Generally, malignant gliomas are not curable and although relatively uncommon, 
malignant gliomas are associated with disproportionately high morbidity and 
mortality. In the past two decades tumor management have improved in a large 
scale in terms of novel approaches such as surgery, radiation and chemotherapy. 
These advances have led for a better quality of patients’ life in variable degrees 
and survival improvement (Jones and Holland, 2010).   
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Glioblastoma (GBM) is one of the most common and lethal primary brain tumor 
which demonstrates a high proliferation rate, aggressive growth pattern and 
largely resistant to chemotherapy (Agnihotri et al., 2013; Gangemi et al., 2009). 
With over 40 years of research in this area, there is only a little improvement 
seen in mortality rates among patients diagnosed with GBM. This has been the 
case due to the intra- and inter-tumoral heterogeneity and the tendency of the 
cancerous cells to infiltrate into the normal brain parenchyma. Besides these, 
blood-brain barrier prevents chemotherapeutic agents from adequately 
penetrating into the tumor mass and leads to suboptimal therapeutic response had 
further complicated the scenario (Stummer et al., 2011). Therefore, it has always 
been a challenge for every researcher to come up with a solution in providing 
effective therapies for the treatment of GBM, dilemma evidenced in median 
survival of 15 months and remained practically unchanged over the past several 
decades (Bleeker et al., 2012). 
 
Currently, researchers are seeking for new substances that may reduce the 
viability of cancer cells, slow tumor growth, and extend life expectancy. 
Therefore, increased interests have been subjected against natural products for 
their importance in sustaining good life of human by preventing or treating 
cancer. Among the apicultural products that possess functionality characteristics 
(antibacterial, anti-inflammatory, antiviral), honey has been widely presented in 
various culture cell lines (Barbarić et al., 2011; Borges et al., 2011; da Silva 
Frozza et al., 2013). Honey can be obtained from honey bees as well as stingless 
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bees. Stingless bees are known as highly eusocial insects with over 500 species 
in 32 genera with probability of 100 more new ones yet to be identified and 
characterized (Michener, 2000; Michener, 2013). 
 
Stingless bees produce precious products such as honey, which is stored in 
propolis-rich cerumen pots. Compounds such as polyphenols (phenolic acids, 
flavonoids and their derivatives), terpenes, steroids, and amino acids are 
particularly interesting in which they are considered as an important part of 
traditional medicine (Küçük et al., 2007). Previous study by Jaganathan and 
colleague had reported a strong cytotoxicity of honey against U87 cell line which 
suggested at possibility of connection between the polyphenols content in the 
honey (Jaganathan and Mandal, 2009b). The paper also proposed that 
polyphenols in honey such as caffeic acid, caffeic acid phenyl ester, chrysin, 
galangin, quercetin, kaempferol, acacetin, pinocembrin, pinobanksin and 
apigenin may be responsible in the anti-proliferative activity observed. Despite 
that, other biochemical compounds found in honey such as the chrysin can be 
used to prevent cancer similar to the action of a breast cancer drug (anastrozole) 
(Galijatovic et al., 2001). However in another study, a dose dependent decrease 
in cell viability of glioma cells was suggested to be caused by Lead (Pb) 
contained in the honey, where Pb was suggested to activate p38MAPK and 
JNK1/2 to start a series of effect in the C6 glioma cells (Posser et al., 2007). 
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Effect of caffeic acid and its ester present have also been proven to play a vital 
role in mechanism of antiproliferative and apoptotic effects on malignant cells in 
various studies done. Rao and colleagues (1992), performed a detailed study by 
synthesizing caffeic acid esters and examined them against 3, 2 -dimethyl-4- 
aminobiphenyl (DMAB, a colon and mammary carcinogen). Another study 
reported on strong repressive effect of CAPE, in which inhibitory effect of CAPE 
was established on TPA-induced tumor promotion by topical application of 
CAPE in CD-I mice (Huang et al., 1996). A study done in Iran, reported that 
honey is capable of inducing apoptosis in bladder cancer cell lines (T24, RT4, 
253J and MBT-2). Ability of honey to inhibit proliferation in these cell lines 
were also showed by using 1-25% of honey concentration, which further 
clarified that honey possesses potential antitumor known as antimetastatic effects 
(Samarghandian et al., 2011). Another similar study conducted in Brazil using 
Tetragonisca fiebrigi stingless bee, has revealed that the bee product exhibits 
antioxidant as well as anti-inflammatory activities. Cytotoxic activity was also 
determined in a concentration-dependent against K562 cells (Campos et al., 
2014). Therefore, these studies suggested for possible importance of the stingless 
bee species honey product in as cancer treatment. 
 
To our knowledge, anticancer activity of stingless bee (Heterotrigona itama sp.) 
has not yet been analyzed. The present study has been chosen to investigate for 
the first time, the cytotoxic effect of Heterotrigona itama sp. honey product on 
human brain cell line. This study is expected to develop the present information 
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on the chemical characterization, anticancer activity of the stingless bee honey 
and to assist in a more focused design of further research, such as aiming at more 
specified applications of this product as a natural adjuvant treatment against 
GBM. Stingless bees’ honeys comprising sugar and water for 95% of the honey 
dry weight along with numerous compounds such as organic acids, proteins, 
amino acids, minerals, polyphenols, vitamins (ascorbic acid) and aroma 
compounds. Pharmacologically active components, especially flavonoids and 
phenolic constituents are thought to contribute towards medicinal benefits of 
these stingless bee honeys (Bogdanov et al., 1996).   
 
This study is aimed to investigate the anti-proliferative as well as pro-apoptotic 
effects of stingless bee honey on two malignant glioma cell lines; (glioblastoma 
multiforme – U87MG and glioma cell with high degree of resistance: dBTRG).  
Additionally, morphological analyses which include light and fluorescence 
microscopy methods were performed.  
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1.2 Rationale of study 
Current treatments for GBMs are with several limitations such as difficulties to 
achieve complete surgical resection, failure in precise drug delivery and also side 
effects which accompany the radiation and chemotherapy (Bonavia et al., 2011; 
Kesari, 2011). Thus newer therapeutic strategies are in urgent need. Failing in 
removing the tumor completely through surgery will cause recurrent cases which 
therefore require adjuvant therapies such as radiation and chemotherapy. 
However, studies shows that though the tumor itself has most deleterious effect 
on cognitive function, radiotherapy may result in additional long term effects 
when high fraction dose is applied as the treatments could not discriminate 
between normal and cancer cells (Auffinger et al., 2012). In some cases, cells are 
becoming resistant to radiation therapy; such that upon clinically approved 
dosage use, tumors could not being eradicated successfully (Baumann et al., 
2009). 
 
Moreover, long term use of chemotherapy drugs such as Temozolomide (TMZ). 
Several studies have reported the roles played by these resistance mechanisms in 
causing cancer resistance against the chemotherapeutic drugs assigned (Ma et al., 
2010). For example, TMZ had been associated with thrombosis and bleeding 
problems (Patel et al., 2013). Other side effects associated with these drugs are 
also devastating such as seizure, numbness, and signs of infections, easy bruising 
and bleeding, loss of appetite, nausea, vomiting and fatigue. Due to this 
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condition, there is an urgent need to find newer anticancer agents to be 
developed into a novel anticancer drug which is able to evade the resistance 
mechanism and unfavourable side effects. 
Among the many herbs and natural products being targeted for these purposes, 
honey is found to be an interesting source of few bioactivities. For examples, 
several studies have shown anticancer properties of stingless bee honey and its 
phenolic components by different mechanisms such as cell cycle arrest as in 
inhibition of cancer cell proliferation in colon cancer (Jaganathan and Mandal, 
2009a), glioma (Lee et al., 2003) and melanoma cancer cell line in G0/G1 phase 
(Pichichero et al., 2010), induction of apoptosis (Jaganathan and Mandal, 2009a), 
induction of mitochondrial stress(Jaganathan and Mandal, 2010), effects on 
tumor necrosis factor (Tonks et al., 2003),  anti-inflammatory and 
immunomodulatory activities (Attia et al., 2008) and anti-mutagenic activity 
(Saxena et al., 2012). Several reports have been made on anticancer activity of 
stingless bee honey from various parts of the globe. Though most of the studies 
were done using the honeybee product (Apis sp), suggesting their various 
bioactivities such as anti-proliferative and pro-apoptotic activity. Little attention 
had been projected towards stingless bee product though stingless bee honeys are 
still being used in traditional medicine in several places such as in Central and 
South America, and Africa (Cortopassi-Laurino et al., 2006). Several studies had 
suggested the likelihood of   therapeutic properties that may be held by stingless 
bee honey which are similar to presently used curative honeys such as honeybee 
(Adams et al., 2008; Borges et al., 2011; Cooper et al., 2000). Other examples 
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include antimicrobial and antiproliferative activities of Tetragonula laeviceps sp.  
reported in Thailand (Umthong et al., 2011; Umthong et al., 2009) and Melipona 
scutellaris sp. from Brazil with similar anticancer  properties (da Cunha et al., 
2013). Therefore, these interesting reports prompted us to study the anticancer 
potential of Heterotrigona itama sp. stingless bee honey, which is found in 
Kelantan, Malaysia.  
 
1.3 Objectives of the study 
 
1.3.1 General Objective: 
 
To study the anticancer effects of Heterotrigona itama sp. honey on human GBM cell 
lines. 
 
1.3.2 Specific Objectives:  
 
1. To evaluate the effect of Heterotrigona itama sp. honey on cell viability of human 
GBM cell lines. 
2. To visualize the effect of Heterotrigona itama sp. honey on morphological changes of 
human GBM cell lines. 
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CHAPTER 2 
 
 
LITERATURE REVIEW 
 
 
2.1 Malignant glioma (Glioblastoma, GBM) 
Cancers are some of the most fatal diseases known to human kinds. Tumors can 
either be malignant or benign, whereby benign tumors are usually harmless to 
body unless it is increasing in mass and start pressing on nearby internal organs 
and tissues (Louis et al., 2007). An example would be brain tumors, which have 
generally stricken deep into psyche of those receiving and those delivering the 
diagnosis. It includes both neoplasms emerging directly from brain (primary 
brain tumor) and those involving the brain as metastatic site (secondary brain 
tumor) which are capable of indirectly damaging healthy cells by crowding other 
parts of the brain, therefore causing inflammation, brain swelling and pressure 
within the skull (Omuro and DeAngelis, 2013). Sixty percent of the tumors 
originate from glial cells (glioma tumor). GBM is a type of malignant brain 
tumor arising from the glial cells of the brain which are responsible in 
surrounding and supporting the brain neurons. These tumor cells grow 
uncontrollably by disobeying normal cell division rules as well as rapidly 
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reproducing, in a restricted nutrient and spaces to grow resulting in invasion and 
metastasis (Agnihotri et al., 2013).  
 
2.1.1 Glioma classification 
Presence of both neoplastic and stromal tissues in GBM had contributed towards 
both histologic heterogeneity and variability in outcomes. This therefore requires 
a better classification of these tumors using molecular studies such as gene-
expression profiling and aids in classification of these tumors to various 
prognostic groups (Wen and Kesari, 2008). In general, glial tumors are 
distinguished by means of their cell type, by location and by grade. Classification 
according to cell type are through close resemblance of which cell they represent 
the most leading to several types such as ependymoma (ependymal cells), 
astrocytomas (astrocytes), oligodendrogliomas (oligodendrocytes) (Huttner, 
2012). GBM are also classified depending on their location whether above or 
below brain membrane called tentorium. The membrane acts as separation of the 
cerebrum and cerebellum, leading to classification such as supratentorial (above 
tentorium) and infratentorial (below tentorium). World Health Organization 
(WHO) had classified higher grade glioma as grades III and IV based on tumor 
histological and immunohistochemical features (Louis et al., 2007). Much 
specifically, anaplastic astrocytomas, anaplastic oligodendrogliomas, and 
anaplastic oligodendroastrocytomas are classified as grade III while GBM and 
other less common variants are classified as grade IV. Glioma classification is 
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illustrated below in Table 1.1. GBMs, being the most aggressive and deadly of 
these tumors had thus become the most common cancer of the central nervous 
system (CNS) accounting for 53% of gliomas overall (Huse and Holland, 2010). 
Lower grade gliomas such as the grade 1 and 2 (benign) are with a better 
prognosis compared to higher grade gliomas. However, lower grade gliomas 
often have higher likelihood of emerging to grade 4 type GBM (Jones and 
Holland, 2012). 
Table 1.1: World Health Organization (WHO) classification of common glial 
tumors in humans. Adapted from (Phillips et al., 2006).  
 WHO 
grade 
Tumor 
histology 
Subtype by 
histology 
Low 
grade 
I 
 
II 
Benign, well 
circumscribed. 
Diffuse 
infiltration, 
low 
proliferation 
Pilocytic 
astrocytoma 
Diffuse 
astrocytoma 
Oligodendroglioma 
Oligodendrocytoma 
High 
grade 
III 
 
 
 
 
 
IV 
Highly 
infiltrative, 
high 
proliferation. 
 
 
 
Highly 
infiltrate, high 
vascular and 
Cellular 
proliferation. 
Anaplastic- 
astrocytoma 
Anaplastic- 
oligoastrocytoma 
Anaplastic-
oligodendroglioma 
 
Glioblastoma- 
Multiforme 
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2.1.2 Incidence, Symptoms 
Annual incidence of glioma is approximately 5 cases per 100,000 people (WHO, 
2008), while, it’s incidence in Malaysia had shown to constantly increase 
through the years with GBMs being the most frequently repeated cases (Yusoff 
et al., 2004). The average age of diagnosis is 65 and found to be common in men 
as compared to women. Low survival rate of GBM patients, ranging between 12 
to 14 months which had made GBM as an urgent subject of cancer research. 
GBM accounts for approximately 60 to 70% of malignant gliomas, 10 to 15% of 
anaplastic astrocytomas and 10% of anaplastic oligodendrogliomas and 
anaplastic oligoastrocytomas. Less common tumors such as anaplastic 
ependymomas and anaplastic gangliogliomas account for the rest (Wen and 
Kesari, 2008). The incidence of these tumors has increased slightly over the past 
two decades especially in the elderly, primarily due to improvements in 
diagnostic imaging (CT and MRI), which have enabled us to detect the tumors in 
advance. Moreover, availability of more neurosurgeons, precise characterization 
of the tumors and also changes in therapy approaches have attributed to elevated 
incidence of detectable cases (Schwartzbaum et al., 2006). Symptoms for GBMs 
are similar to other malignant brain cancers, which include headache, seizure, 
memory loss, and physical weakness such as loss of muscle control, visual 
symptoms, language problems and cognitive decline (Behin et al., 2003).  The 
exact cause of GBM is still inconclusive. However, 5% of the tumors have 
known hereditary factors. Genetic alterations in glioma have been correlated with 
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pathways of cancer hallmarks such as cell proliferation, cell survival, invasion 
and angiogenesis (Furnari et al., 2007; Hanahan and Weinberg, 2011).  
 
2.1.3 Molecular pathogenesis 
GBM are generally classified into two subtypes (primary GBM and secondary 
GBM) in reference to their biologic and genetic differences. Frequently 
occurring in elderly patients, primary GBMs are featured by EGFR amplification 
and mutations, loss of heterozygosity of chromosome 10q, deletion of the 
phosphatase and tensin homologue on chromosome 10 (PTEN), as well as p16 
deletion (Wen and Kesari, 2008). Whilst, secondary GBM often occurring in 
younger patients, are characterized by mutations in the p53 tumor suppressor 
gene (TSG), overexpression of the platelet derived growth factor receptor 
(PDGFR), abnormalities in the p16 and retinoblastoma (Rb) pathways, and loss 
of heterozygosity of chromosome 10q. Both primary and secondary subtypes of 
GBM differ from each other in terms of transcriptional patterns and aberrations 
in the DNA copy (Wen and Kesari, 2008).  
 
2.1.4 Current treatments 
Standard treatments applied for GBMs are maximum resection of the tumor by 
surgery, chemotherapy using drug known as temozolomide and radiotherapy. 
Though malignant gliomas cannot be completely eliminated surgically because 
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of their infiltrative nature, patients should undergo maximal surgical resection as 
possible to ensure complete elimination of the tumor (Steiger et al., 2000). 
Conversely, due to heterogeneity of the tumor, goal of these treatments are hard 
to achieve and in almost 80% of the cases there will be recurring tumor (Olar and 
Aldape, 2014). Patients’ survival rate in GBMs is also very poor and had not 
shown any improvement for the past 20 years. Thus, urge to develop therapies 
for brain cancers in neuro-oncology field was put up front in hope for 
improvement of the patients’ survival rate. To test the experimental therapies, 
most of the studies require the use of animal as well as in vitro models of brain 
tumor.  
 
2.1.5 Alternative treatment options 
Chemotherapy consisting drugs such as procarbazine, lomustine and vincristine 
is known as the most common combination regime treating higher grades 
gliomas. Additionally, carmustine-polymer wafers were also approved by FDA 
in 2002, where the wafer would be placed at the tumor location for initial 
treatment (Bota et al., 2007). Survival rate is higher in those underwent radiation 
therapy than patients who did not (Stupp et al., 2002). Adding up to the 
evidence, final result of randomized phase 3 trial on prolonged survival rate on 
those received adjuvant temozolomide with radiotherapy has also been reported 
(Stupp et al., 2005). Patients with methylated MGMT promoter adjuvant with 
chemotherapy revealed longer survival rate (Hegi et al., 2005).  However, lesser 
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aggressive treatments are opted for patients of 70 years and above (Ahmed et al., 
2014). 
 
2.2 Honey 
Honey is one of the oldest best loved sweetening agents produced by honeybees 
and stingless bees. Use of natural honey as food and medicine products has long 
been present from time immemorial by ancient Egyptians, Assyrians, Greeks and 
Romans in which they used honey for wounds and diseases of intestine (Bent, 
2013; Dhinsa et al., 2013; SHARMA et al., 2012). Though honey has been long 
appreciated for its medicinal properties in the earlier days, its use in modern 
medicine is very much limited due to restricted amount of studies and scientific 
supports (Mirzaie et al., 2012). However, in the past decade, benefits of honey 
had become more dedicated towards its curative properties, few examples of 
most remarkable discoveries made are antibacterial (Alvarez-Suarez et al., 2010; 
Jeffrey and Echazarreta, 1996), antioxidant (Hegazi and Abd El-Hady, 2009), 
anti-inflammatory (Medhi et al., 2008; Tonks et al., 2003) and anticancer 
properties (Al-Mamary et al., 2002; Ghashm et al., 2010; Swellam et al., 2003; 
Wen et al., 2012). Moreover in recent study, also revealed anti-cancer property 
of Malaysian jungle honey on various cell lines such as human breast cancer, 
cervical, oral and osteosarcoma cell lines (Fauzi et al., 2011). Anti-proliferative 
property was reported in several papers (Fernandez-Cabezudo et al., 2013; 
Samarghandian and Samini, 2014). Honey is therefore classified into both 
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nutraceutical and therapeutic food categories, meaning that honey is capable of 
serving sufficient quantities of nutrients to satisfy particular organic needs, thus 
reducing risks of developing several illnesss. 
 
2.2.1 Heterotrigona itama sp. (stingless bee) 
With majority of studies are focusing on honey produced by the honeybee, little 
attention has been given towards honey obtained from stingless bees. Currently, 
stingless bee honeys are still being used in traditional medicine in several places 
such as in Central and South America, and Africa (Cortopassi-Laurino et al., 
2006). Increasing evident had suggested the possibility of   therapeutic properties 
that may be held by stingless bee honey which are similar to currently used 
medicinal honeys such as honeybee (Adams et al., 2008; Cooper et al., 2000; 
George and Cutting, 2007). Therefore, the main goal of using Heterotrigona 
itama sp (honey product) in our current study is to examine potential anti-cancer 
property of the stingless bees, which is available in Malaysia and commonly 
manufactured by local bee keepers. To our knowledge, this is the first study to 
evaluate the bioactivities of Heterogena itama sp. 
 
Belonging to five different genera (Melipona, Trigona, Meliponula, Dectylurina 
and Lestrimelitta), the stingless bees are a group of eusocial insects which plays 
a vital role in pollination process (Heard, 1999). Trigona is the largest genus of 
stingless bees, formerly including many more subgenera than the present 
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assemblage; many of these former subgenera have been elevated to generic status 
(Gupta, 2014). There are approximately 150 species presently included in the 
genus, in 11 subgenera. They differ from those groups now excluded in only 
minor structural details, primarily of the hind leg. Meliponines, are a large group 
of bees, comprising the tribe Meliponini (sometimes called stingless honey bees) 
in the family Apidae, and closely related to the common honey bees, carpenter 
bees, orchid bees and bumblebees. Stingless bees usually nest in hollow trunks, 
tree branches, underground cavities, or rock cavities, old rubbish bins, water 
meters, and storage drums. Many beekeepers keep the bees in their original log 
hive or transfer them to a wooden box, as this makes it easier to control the hive 
(Vit et al., 2013).    
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(a) 
 
 (b) 
 
Figure 2.1: (A and B) Shows stingless bee Trigona image (top right) and 
method of stingless bee honey acquisition from its pots filled with honey 
(bottom) Adapted from www.lebahkelulut.com. 
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2.2.2 Medicinal properties of stingless bee honey 
Lack of stingless bee honey quality standards resulted in no publishing on quality 
control declaration for consumers, however had encouraged more studies using 
stingless bee products to be done (Chuttong et al., 2016).  
 
Stingless bees’ honeys are known to have pharmacologically active components 
which are thought to be contributing to the medicinal benefits of these honeys. 
Sugars are the main constituents, comprising about 95% of the honey dry weight. 
Besides sugars and water, the honey contains numerous compounds such as 
organic acids, proteins, amino acids, minerals, polyphenols, vitamins (ascorbic 
acid) and aroma compounds (Bogdanov et al., 2008; Chuttong et al., 2016). 
Particularly interesting are compounds such as polyphenols (phenolic acids, 
flavonoids and their derivatives), terpenes, steroids, and amino acids, which are 
considered as an important part of traditional medicine. Most imperative 
compounds being studied are phenolic acids and flavonoids, which are believed 
to contribute to the high antioxidant activity in the honey (Küçük et al., 2007). A 
review paper published by Othman (2012) also suggests that therapeutic 
properties of honey are capable of counteract the multi-factorial causes of 
carcinogenesis (excess free radical production, chronic infection, chronic 
inflammation, decreased immune level, chronic ulcers and hereditary). The 
inverse relationship between honey and cancer is illustrated in Figure 2.2. 
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Figure 2.2: Inverse relationship between honey and cancer. Modified from: 
(Othman, 2012). 
 
To compare physiochemical properties of stingless bee honey with normal 
honey, it is worthwhile taking a look into a study conducted in Thailand 
(Chuttong et al., 2016).  Their study had successfully analyzed 28 stingless bee 
honey samples and comparison was made to A.mellifera sp. honey standard. 
Results revealed that these stingless bee honeys had higher moisture content, 
high ash content, lower pH, higher acidity, lower diastase activity and lower total 
carbohydrates as compared to normal honeys’ physiochemical composition. The 
Properties of honey   
Has high antioxidant 
Is a scavenging agent for toxic free 
radicals 
Is natural antimicrobials 
Is natural immune booster 
Is natural anti-inflammatory agent 
Is 'fixer' for chronic ulcers and 
wounds 
Has potential as cancer therapeutic 
agents 
Causes of cancer 
Accumulation of toxic free radicals 
reactive oxygen species due to 
smoking, alcohol, obesity and 
chronic infections 
Chronic infections; bacteria, virus 
and fungus 
Low immune status; diabetes, 
chronic illness 
Chronic inflammation; colorectal 
carcinoma in Chron's disease 
Chronic nonhealing ulcers; 
squamous cell carcinoma developing 
in chronic traumatic wounds 
Genetic inheritance 
Cause unknown 
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study served as the first study reporting physicochemistry from those south east 
Asian stingless bee species (Chuttong et al., 2016).  
 
Besides that, another study from Brazil comprised of physiochemical data from 
152 stingless bee honey samples collected from year 1964 was evaluated for 
quality control proposal of several species of stingless bee honeys (Souza et al., 
2006). Summary of the physicochemical parameters taken into account are 
shown below in figure 2.3. 
 
Figure 2.3: Summary of stingless bee honey composition (Souza et al., 2006). 
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2.2.3 Polyphenols 
Polyphenols comprise a wide variety of molecules with several hydrogenated 
substituents as well as other their functional derivatives on the aromatic rings; 
such as phenolic acids and phenolic alcohols. Polyphenols are divided into 
several classes, according to the number of phenolic rings present and to the 
structural elements connecting the rings to one another (Grassi et al., 2009). It is 
mainly a supersaturated sugar solution, with more than 95% of its dry mass 
consisting of sugar, although different valuable nutrients such as vitamins, 
minerals, enzymes, flavouring organic compounds, free amino acids and 
numerous volatile compounds constitute minor components (Baroni et al., 2006; 
Makawi et al., 2009). However, it is this smaller fraction of the overall 
composition that is responsible for honey’s organoleptic and nutritional 
properties (Manyi-Loh et al., 2011). Honey composition varies due to the 
differences in plant types, climate and environmental conditions (Küçük et al., 
2007). Honey composition is tightly associated to its botanical source and also to 
the geographical area, because soil and weather determine melliferous flora. 
Depending on the botanical origin, honey could be classified as: (a) floral, when 
it is derived from the nectar of flowering plant, or (b) non-floral (honeydew) 
when it is derived from sweet deposits secreted by living parts of plants or 
excreted onto them by sap-sucking insects (Manyi-Loh et al., 2011). The main 
group of phenolic includes derivatives of cinnamic acid, cumarins as well as 
flavonoids. Figure 2.4 shows chemical structure of polyphenols. 
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Figure 2.4: Chemical structures of phenolic acid (Erejuwa et al., 2014). 
 
2.2.3 (a) Mechanism known to attributing anti-cancer activity 
Caffeic acid is an example of chemical compound consisting phenol group. Effect 
of caffeic acid and its ester group in honey has been proven to play a vital role in 
mechanism of antiproliferative and apoptotic effects on various malignant cells. 
Caffeic Acid Phenylethyl Ester (CAPE) undergoes oxidation by tyrosinase 
through two-electron oxidation to quinone and oxidized by HRP/H2O2 through 
one-electron oxidation to a semiquinone. CAPE toxicity towards SK-MEL-28 
human melanoma cells was significantly enhanced by dicoumarol (DC), a 
diaphorase inhibitor, and 1-bromoheptane (BH), a GSH depleting agent. Ascorbic 
acid (AA), nicotinamide adenine dinucleotide (NADH), and glutathione (GSH) 
were depleted as a result of CAPE oxidation mediated by tyrosinase bioactivation. 
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Ethylenediamine, an o-quinone trap, reacts with CAPE o-quinone, preventing 
NADH and AA oxidation (Kuduguntil et al., 2010). 
Rao et al. 1992, performed a detailed study by synthesizing caffeic acid esters 
and examined them against the 3, 2 -dimethyl-4- aminobiphenyl (DMAB, a 
colon and mammary carcinogen). Huang et al.1996, showed the strong 
repressive effect of caffeic acid phenethyl ester (CAPE), where inhibitory effect 
of CAPE was established on TPA-induced tumor promotion by topical 
application of CAPE in CD-I mice. The effects of caffeic acid phenethyl ester 
(CAPE) were first studied in carivcal carcinoma cells. CAPE showed cells 
growth inhibition by arresting the S phase. The arrest was associated with 
elevated expression of E2F1, Apaf-1 and reduced expression of Mc1-1. Besides 
that, cyclin A and E expression were increased while expression of cyclin B was 
decreased. The overall effects resulted in inhibition of the cell growth and thus 
led to cell cycle arrest (Kuo et al., 2013). 
In other study investigating cytotoxicity effect of CAPE on C6 glioma cells done, 
the study revealed that the glioma cells underwent internucleosomal DNA 
fragmentation upon 24hrs treatment with CAPE. Further study also reported that 
CAPE is capable to cause p53 dependent apoptosis in the glioma cells (Lee et al., 
2003). Besides, in-vitro biochemical mechanism of caffeic acid phenylethyl ester 
(CAPE) toxicity and eight hydroxycinnamic/caffeic acid derivatives in-vitro, 
using tyrosinase enzyme as a molecular target in human SK-MEL-28 melanoma 
cells was also investigated as shown below in Figure 2 (Kudugunti et al., 2010). 
